Zhitong Finance App News, Tiantan Biology (600161.SH) issued an announcement. Recently, “Human Coagulation Factor IX” developed by Chengdu Rongsheng Pharmaceutical Co., Ltd. (“Chengdu Rongsheng”), a subsidiary of the company, completed phase III clinical trials and obtained a clinical trial summary report.

According to reports, clinical trial results of human coagulation factor produced by Chengdu Rongsheng show that the main PK parameters of the drug are similar to data from similar marketed products. After infusion, it can effectively increase the level of coagulation factor in patients with hemophilia B, improve the coagulation function of patients with hemophilia B, improve the bleeding symptoms and signs of patients with hemophilia B, and can effectively control bleeding in patients with hemophilia B. At the same time, safety results show that this product has good safety for patients with hemophilia B during clinical application.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.